摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3E)-N-[(2R)-2-hydroxy-3-piperidin-1-ylpropoxy]-1-oxidopyridin-1-ium-3-carboximidoyl chloride | 289893-25-0

中文名称
——
中文别名
——
英文名称
(3E)-N-[(2R)-2-hydroxy-3-piperidin-1-ylpropoxy]-1-oxidopyridin-1-ium-3-carboximidoyl chloride
英文别名
——
(3E)-N-[(2R)-2-hydroxy-3-piperidin-1-ylpropoxy]-1-oxidopyridin-1-ium-3-carboximidoyl chloride化学式
CAS
289893-25-0
化学式
C14H20ClN3O3
mdl
——
分子量
313.78
InChiKey
SGEIEGAXKLMUIZ-ZPTIMJQQSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    93 - 95o C
  • 沸点:
    539.2±60.0 °C(Predicted)
  • 密度:
    1.32±0.1 g/cm3(Predicted)
  • 溶解度:
    酸水溶液(微溶)、DMSO(微溶)、甲醇(微溶)

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    21
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.57
  • 拓扑面积:
    70.5
  • 氢给体数:
    1
  • 氢受体数:
    5

SDS

SDS:4f021e64cf8a3fcdd71abc573a5d794e
查看

制备方法与用途

生物活性

Arimoclomol (BRX-220 free base) 是一种热休克蛋白 (HSP) 的共诱导剂。它通过增强 HSP 表达来保护运动神经元,进而直接影响蛋白质聚集及清除错误折叠和装配的蛋白。

靶点
HSP
体内研究

Arimoclomol (BRX-220; 20 mg/kg;经口给药5天) 在胆囊收缩素八肽(CCK)诱导的急性胰腺炎中表现出保护作用。

实验信息
动物模型 雄性Wistar大鼠,体重240至270克
剂量 20 mg/kg
给药方式及天数 胃内给药,连续5天
结果 具有对抗CCK诱导的急性胰腺炎的作用

文献信息

  • HSP90 INHIBITING INDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF
    申请人:Bertin Luc
    公开号:US20120010241A1
    公开(公告)日:2012-01-12
    The invention relates to novel products having formula (I), wherein: R4 represents H, CH3, CH2CH3, CF3, F, Cl, Br, I; Het represents a heterocycle optionally substituted by one or more R1 or R′1 radicals selected from H, halogen, CF3, nitro, cyano, alkyl, hydroxy, mercapto, amino, alkylamino, dialkylamino, alkoxy, phenylalkoxy, alkylthio, carboxy that is free or sterified with an alkyl radical, carboxamide, CO—NH(alkyl), CON(alkyl)2, NH—CO-alkyl, sulfonamide, NH—SO2-alkyl, S(O)2-NHalkyl, S(O2)-N(alkyl)2, all of the alkyl, alkoxy and alkylthio radicals being optionally substituted; R being selected from the group comprising (A′), (B), (C), (D) and (F), wherein W1, W2, W3 represent independently CH or N, X represents O, S, NR2, C(O), S(O) or S(O)2; V represents H, Hal, —O—R2 or —NH—R2 with R2 representing H, alkyl, cycloalkyl or heterocycloalkyl, optionally substituted; said products being in all isomer forms, as well as the salts and intended for use as drugs.
    本发明涉及具有公式(I)的新产品,其中:R4代表H,CH3,CH2 ,CF3,F,Cl,Br,I;Het代表一个杂环,可选地由一个或多个R1或R'1自由基取代,这些自由基选自H,卤素, ,硝基,腈基,烷基,羟基,巯基,基,烷基基,二烷基基,烷氧基,苯基烷氧基,烷基醚,游离或与烷基自由基酯化的羧基,羧酰胺,CO—NH(烷基),CON(烷基)2,NH—CO-烷基,磺酰胺,NH—SO2-烷基,S(O)2-NH烷基,S(O2)-N(烷基)2,所有烷基,烷氧基和烷基醚自由基都是可选取代的;R选自包括(A′),(B),(C),(D)和(F)的组,其中W1,W2,W3独立代表CH或N,X代表O,S,NR2,C(O),S(O)或S(O)2;V代表H,Hal,—O—R2或—NH—R2,R2代表H,烷基,环烷基或杂环烷基,可选取代;所述产品为所有异构体形式,以及盐,用于作为药物使用。
  • NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF
    申请人:RUXER Jean-Marie
    公开号:US20110166169A1
    公开(公告)日:2011-07-07
    The invention relates to the novel substances in Formula (I): wherein Het is a heterocycle optionally substituted by one or a plurality of radicals R1 or R′1; R is selected from the group comprising Formula (A′), (B), (C), (D), or (E), with R1 and/or R′1 selected from H, halogen, CF3, nitro, cyano, alkyl, hydroxyl, mercapto, amino, alkylamino, dialkylamino, alkoxy, phenylalcoxy, alkylhio, or carboxy that is free or esterified by an alkyl, carboxamide, CO—NH(alkyl), CON(alkyl)2, NH—CO-alkyl, sulfonamide, NH—S02-alkyl, S(0)2-NHalkyl, or S(02)-N(alkyl)2 radical; all these radicals are optionally substituted; W1, W2, and W3 independently are CH or N; X is 0, S, NR2, C(O), S(O), or S(0)2; Z is optionally substituted H, Hal, -0-R2 or —NH—R2 with R2 being H, alkyl, cycloalkyl, or heterocycloalkyl; and these substances are all isomeric forms and salts thereof, used as drugs.
    该发明涉及式(I)中的新物质:其中Het是一种杂环,可选择地由一个或多个基团R1或R′1取代;R从包括式(A′)、(B)、(C)、(D)或(E)的基团中选择,其中R1和/或R′1从H、卤素、CF3、硝基、基、烷基、羟基、巯基、基、烷基基、二烷基基、烷氧基、苯基氧基、烷基或自由或被烷基、羧酰胺、CO—NH(烷基)、CON(烷基)2、NH—CO-烷基、磺酰胺、NH—S02-烷基、S(0)2-NH烷基或S(02)-N(烷基)2基团中选择;所有这些基团可选择地被取代;W1、W2和W3独立地是CH或N;X是0、S、NR2、C(O)、S(O)或S(0)2;Z是可选择地取代的H、卤素、-0-R2或—NH—R2,其中R2是H、烷基、环烷基或杂环烷基;这些物质都是同分异构体和其盐,用作药物。
  • [EN] NOVEL SUBSTITUTED PIPERIDONES AS HSP INDUCERS<br/>[FR] NOUVELLES PIPÉRIDONES SUBSTITUÉES EN TANT QU'INDUCTEURS DE HSP
    申请人:TORRENT PHARMACEUTICALS LTD
    公开号:WO2009004650A1
    公开(公告)日:2009-01-08
    The present invention relates to novel compounds of formula (I) or (II), their pharmaceutically acceptable salts and their hydrates, solvates, stereoisomers, conformers, tautomers, polymorphs and prodrugs and also pharmaceutically acceptable compositions containing them Wherein R1, R2, R3, R4, R5, R6 and R7 are as defined in the specification. The compounds of the present invention are HSP inducers and by virtue of this effect, useful for the treatment of various diseases accompanying pathological stress. The present invention also relates to a process for the preparation of the said novel compounds. The invention also relates to the use of the above-mentioned compounds for the preparation of medicament for use as pharmaceuticals.
    本发明涉及式(I)或(II)的新化合物,它们的药学上可接受的盐及其合物、溶剂合物、立体异构体、构象异构体、互变异构体、多晶型和前药,以及含有它们的药学上可接受的组合物,其中R1、R2、R3、R4、R5、R6和R7如规范中所定义。本发明的化合物是HSP诱导剂,由于这种作用,对于治疗伴随病理性压力的各种疾病是有用的。本发明还涉及一种制备上述新化合物的方法。该发明还涉及上述化合物的用途,用于制备用作药物的药物。
  • [EN] SMALL MOLECULE OXIDIZERS OF PDI AND THEIR USE<br/>[FR] OXYDANTS DE LA PDI À PETITE MOLÉCULE ET LEUR UTILISATION
    申请人:UNIV COLUMBIA
    公开号:WO2016118639A1
    公开(公告)日:2016-07-28
    The present invention provides a method for treating or ameliorating the effects of a neurodegenerative disorder in a subject in need thereof comprising administering to the subject an effective amount of a compound selected from the group consisting of combinations thereof, or an N-oxide, crystalline form, hydrate, or pharmaceutically acceptable salt thereof. The present invention also provides a method for treating or ameliorating the effects of a condition associated with increased protein disulfide isomerase (PDI) activity and a method of modulating PDI activity in a cell. The present invention also provides compounds, salts, compositions and kits useful for the provided methods.
    本发明提供了一种治疗或改善需要的受试者神经退行性疾病影响的方法,包括向受试者施用所选化合物组合中的有效量,或其N-氧化物、结晶形式、合物或药用可接受盐。本发明还提供了一种治疗或改善与增加蛋白二键异构酶(PDI)活性相关的病症的方法,以及调节细胞中PDI活性的方法。本发明还提供了用于所述方法的化合物、盐、组合物和试剂盒。
  • [EN] NEUROPROTECTIVE PDI MODULATING SMALL MOLECULES AND METHODS OF USE THEREOF<br/>[FR] PETITES CELLULES MODULANT LE PDI NEUROPROTECTEUR ET LEURS MÉTHODES D'UTILISATION
    申请人:UNIV COLUMBIA
    公开号:WO2020113222A1
    公开(公告)日:2020-06-04
    The present disclosure provides, inter alia, compounds and compositions having the formula (I) as defined herein. Methods of using and making such compounds and compositions are also provided. The present disclosure further provides screening methods, including detectable probes as well as diagnostic methods and methods for monitoring the progress of a disease, such as a neurodegenerative disease.
    本公开提供具有以下式(I)所定义的化合物和组合物,等等。还提供使用和制备这种化合物和组合物的方法。本公开还提供筛选方法,包括可检测的探针,以及诊断方法和监测疾病进展的方法,如神经退行性疾病。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S,2'S)-(-)-[N,N'-双(2-吡啶基甲基]-2,2'-联吡咯烷双(乙腈)铁(II)六氟锑酸盐 (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 (1'R,2'S)-尼古丁1,1'-Di-N-氧化物 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸氯苯那敏-D6 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 韦德伊斯试剂 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非布索坦杂质66 非尼拉朵 非尼拉敏 雷索替丁 阿雷地平 阿瑞洛莫 阿扎那韦中间体 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 镉,二碘四(4-甲基吡啶)- 锌,二溴二[4-吡啶羧硫代酸(2-吡啶基亚甲基)酰肼]-